SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A record fiscal-quarter earnings beat and raised full-year outlook, supported by strong bookings and AI-chip testing demand, drove AEHRs sharp rally. Traders welcomed the results and AI growth prospects, while others questioned the valuation and whether the rebound can hold.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys Q3 results triggered a sharp selloff as investors focused on revenue and GMV misses and signs of moderating growth, despite stronger earnings and cash generation. Traders are split between concerns that a high valuation leaves little room for slower growth and calls that the drop is an overreaction, with dip-buyers pointing to the rebound.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals first profitable quarter and continued Rezdiffra sales growth are in focus, but shares are falling as traders debate the pace of adoption: some see low market penetration as substantial runway, while others worry reimbursement delays and the need for clinical-outcomes evidence could prolong the wait. Speculation about a takeover also appears, but no deal is confirmed.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the following business segments: Cannabis and Plant Propagation. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Organigrams agreement to acquire Aurora has triggered a sharp rally, overtaking Curaleafs earlier bid. Traders are celebrating the deal while debating whether Curaleaf could counterbid and whether the agreed terms limit further upside for Aurora shareholders.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong quarterly results and raised outlook have been overshadowed by a sharp share-price pullback, as traders focus on slower contract bookings and the stocks premium valuation. The community is split between concerns that future growth may cool and bullish calls to buy the dip, pointing to accelerating revenue and commercial AI demand.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Call-heavy options activity and recent momentum have drawn attention to RIG, amid discussion of Valaris merger progress and offshore drilling contract wins. Bullish traders see the merger, growing backlog and high short interest as potential upside drivers, while skeptics cite dilution, debt and a pattern of rallies fading.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDBs CEO abruptly leaving for Meta triggered a sharp selloff and debate over leadership risk, despite the company reaffirming its outlook and returning former CEO Dev Ittycheria as interim chief. Traders are split between viewing the drop as an overreactionwith investor-day AI product updates and expanded buybacks supporting a reboundand seeing continued uncertainty around management and valuation.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Rokus strong Q3 earnings beat, with growth in its platform and advertising business, is drawing attention, but traders say the pending Fox acquisition and lack of forward guidance may limit the stocks response. Reactions are mixed between optimism about the operating results and frustration that the deal caps Rokus standalone upside, with regulatory review adding uncertainty.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins quarterly results and newly approved share-repurchase program are driving attention, with traders highlighting stronger profitability and customer growth while debating persistent same-store-sales weakness. The reaction is split between optimism about the business and frustration that the OTC listing and lack of a relisting timeline continue to weigh on the share price.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles equity-and-bond financing for its AI data-center expansion is driving discussion, with traders debating whether it clears a funding overhang or adds to dilution, debt and cash-flow risks. The sharp rebound has drawn bullish calls that the financing is behind the company, while skeptics remain concerned about whether AI spending will generate returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The decline appears tied to a cautious reaction to Q3 results: traders flagged the lack of guidance and concerns that Rezdiffra adoption and reimbursement may take time, despite $431.3 million in quarterly sales and Madrigals first profitable quarter. Some also focused on the need for clinical-outcomes evidence, with MAESTRO-NASH Outcomes data expected in late 2027.

Madrigal (MDGL) Q3 Earnings and Revenues Beat Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +267.89% and +7.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next 

Equity

Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Key PointsMadrigal's only commercial drug, Rezdiffra, continues to grow sales...

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off

Key PointsMASH cirrhosis could significantly expand Rezdiffra's addressable market...

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.

Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

$MDGL Q3 &#39;26 Earnings Results &amp; Recap

Madrigal says the U.S. F2-F3 MASH market is on track for more than 30% growth by YE26; MAESTRO-CSPH initiation is expected in the first half of 2027, subject to regulatory discussions.

Stocktwits

 Q3 '26 Earnings Results & Recap

Madrigal says the U.S. F2-F3 MASH market is on track for more than 30% growth by YE26; MAESTRO-CSPH initiation is expected in the first half of 2027, subject to regulatory discussions.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Madrigal says the U.S. F2-F3 MASH market is on track for more than 30% growth by YE26; MAESTRO-CSPH initiation is expected in the first half of 2027, subject to regulatory discussions.

Madrigal's SG&A increased with Rezdiffra commercial investment, cash and marketable securities were lower than Dec. 31, 2025, and Madrigal identifies regulatory, trial-enrollment, safety, and Rezdiffra market-acceptance risks.

Madrigal reported 50% revenue growth and net income; Rezdiffra patient counts nearly doubled and the addressable market was growing, while a new Phase 3 trial was planned and analyses found improved histology across genetic variants.

Bullish Sentiment

<ul class="summary-bullets"><li>Vertex will report results on Monday, putting Journavx and Casgevy sales and its $10 billion Crinetics acquisition in focus.</li><li>Pfizer and BioNTech report on Tuesday, with Pfizer’s newer medicines and recent cancer-treatment advances drawing attention.</li><li>Amgen reports Tuesday and Novo Nordisk follows on Wednesday, spotlighting MariTide’s development and Wegovy sales.</li></ul><p>Biotech stocks head into a busy earnings week after beating the broader market, with Pfizer, Novo Nordisk and Moderna set to report earnings alongside a fresh round of cancer-treatment data.&nbsp;</p><p>Healthcare and biotech rallied the previous week, with the&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> gaining 5%, the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> climbing 4%, and the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rising 3%. Comparatively, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> fell 0.6%, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> dropped 2%.</p><p><img src="https://news.stocktwits-cdn.com/koyfin_20261102_072345224_2e2499ab82.png" alt="koyfin_20261102_072345224.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>What To Watch</td></tr><tr><td>Nov.2</td><td>VRTX</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>PFE / AMGN / BNTX / MDGL</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>SITC</td><td>Regular abstracts become public&nbsp;</td></tr><tr><td>Nov.4</td><td>NVO</td><td>Q3 results</td></tr><tr><td>Nov.4 - Nov.8</td><td>SITC</td><td>Cancer-immunotherapy meeting in Phoenix</td></tr><tr><td>Nov.5</td><td>IOVA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>MRNA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>SITC / IMCR / CADL</td><td>Late-breaking abstracts release; Immunocore and Candel presentations</td></tr><tr><td>Nov.7</td><td>IMCR / CADL</td><td>Immunocore oral presentation and Candel glioblastoma findings</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Vertex Looks Beyond Cystic Fibrosis</strong></h2><p>Vertex Pharmaceuticals will report results on Monday after the close, with investors looking for more growth from medicines outside its core cystic-fibrosis business.</p><p>Its non-opioid pain drug Journavx brought in $49.6 million in second-quarter sales, while gene-editing treatment Casgevy generated $76.4 million. In August, Vertex raised its full-year revenue forecast to $13.1 billion to $13.2 billion, including at least $500 million from the two drugs. That forecast did not include its $10 billion acquisition of Crinetics Pharmaceuticals, completed Sept.1. The deal added Palsonify, a once-daily pill for acromegaly, a disorder caused by excess growth hormone.&nbsp;</p><h2 class="st-heading-2"><strong>Pfizer Puts Its Cancer Business To The Test</strong></h2><p>Pfizer (PFE) will report on Tuesday, after a busy week for its cancer business. The FDA cleared Talzenna plus Xtandi for earlier use in metastatic prostate cancer with certain DNA-repair gene mutations. The next day, Pfizer said Elrexfio helped patients live longer without their multiple myeloma worsening in a Phase 3 trial against standard treatments. Researchers are still collecting data to determine its effect on overall survival.</p><p>For the earnings report, the question is whether newer medicines can keep making up for weaker COVID-related sales. Revenue from Pfizer’s launched and acquired products grew 18%, excluding currency effects, in the second quarter, helping the company raise the midpoint of its annual revenue forecast by $500 million.</p><p>BioNTech, Pfizer’s COVID-vaccine partner, also reports Tuesday.</p><h2 class="st-heading-2"><strong>Amgen And Novo Bring Obesity Back Into View</strong></h2><p>Amgen (AMGN) will report on Tuesday after the close, with an update on its obesity drug MariTide among the items to watch. Its Phase 3 Maritime program is studying weight management as well as cardiovascular disease, heart failure and sleep apnea. A separate trial is testing injections every eight weeks or quarterly in patients switching from weekly Tirzepatide or Semaglutide. Less frequent dosing could give patients another reason to choose the treatment if it wins approval.</p><p>Novo Nordisk (NVO) will report on Wednesday, with sales of the Wegovy pill and higher-dose injection offering a check on demand. Weekly U.S. prescriptions for the pill topped 265,000 by mid-July. Novo raised its outlook in August, though it still expected adjusted sales and operating profit to range from a 6% decline to no growth, excluding currency effects.</p><p>Madrigal Pharmaceuticals (MDGL) also will report on Tuesday, giving investors a look at demand for its liver-disease drug Rezdiffra.</p><h2 class="st-heading-2"><strong>Iovance Balances Melanoma Sales With Lung-Cancer Plans</strong></h2><p>Iovance Biotherapeutics (IOVA) will report on Thursday. Investors will get an update on Amtagvi, a treatment that uses patients’ own immune cells to fight advanced melanoma, as the company works to expand into lung cancer.</p><p>Results released last month showed a 24.6% response rate among 69 previously treated lung-cancer patients. That rose to 59.1% in a 22-patient subgroup identified using tumor genetics and smoking history. Iovance plans to begin enrolling its Positility cohort in November to test that selection strategy prospectively. A filing for Lifileucel in the broader previously treated lung-cancer population is planned for 2027.</p><h2 class="st-heading-2"><strong>Moderna’s Earnings Go Beyond Vaccine Sales</strong></h2><p>Moderna (MRNA) will report on Friday, with investors weighing seasonal vaccine sales alongside progress on its personalized cancer vaccine. The company previously targeted up to 10% revenue growth for 2026 and expected about 55% of its second-half revenue to come in the third quarter.</p><p>Its update could also bring more detail on regulatory plans for Intismeran Autogene. Last month, Moderna and Merck (MRK) said the experimental vaccine, combined with Merck’s immunotherapy Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone in a Phase 3 trial. Overall-survival data are still being collected.</p><h2 class="st-heading-2"><strong>New Cancer Findings Arrive At SITC</strong></h2><p>The Society for Immunotherapy of Cancer’s annual meeting and pre-conference programs run Nov.4-Nov.8 in Phoenix. Regular research abstracts become public on Tuesday, followed by late-breaking findings on Friday.</p><p>Immunocore (IMCR) will present early results for Brenetafusp alone and with Kimmtrak in metastatic uveal melanoma, an eye cancer that has spread. Both drugs help direct immune cells called T cells to attack cancer. Additionally, Candel Therapeutics (CADL) will present lung-cancer findings Friday in patients whose disease progressed despite earlier immunotherapy. On Saturday, it will share early findings in recurrent glioblastoma, an aggressive brain cancer.</p><h2 class="st-heading-2"><strong>Inovio Gets FDA Approval As Agios Faces A Delay</strong></h2><p>Two names from last week’s FDA watchlist head into November with different outcomes: an approval for Inovio Pharmaceuticals (INO) and a longer wait for Agios Pharmaceuticals (AGIO).</p><p>On Friday, the FDA granted accelerated approval to Inovio’s Voceryq, formerly INO-3107, for adults with recurrent respiratory papillomatosis. The rare HPV-related disease causes recurring airway growths that can require repeated surgery.&nbsp;</p><p>Meanwhile, the FDA extended its review of Agios’ Mitapivat for sickle cell disease to Feb.1, 2027, from Nov.1. The agency is considering whether a risk-management program is needed and classified additional safety information as a major amendment, triggering the three-month extension.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-tsmc-terafab-talks-capex-efficiency-greatly-underestimated/cNG9KfcR92f">SPCX Stock Jumps Overnight: Musk Reportedly Revives TSMC Terafab Talks — Says Capex Efficiency Is ‘Greatly Underestimated’&nbsp;</a></p>

Biotech Stocks Beat The S&P500 – Can Pfizer, Novo And Moderna Earnings Keep The Rally Going?

Agios Pharmaceuticals Inc

AMGEN Inc.

BioNTech SE - ADR

Candel Therapeutics Inc

iShares Biotechnology ETF

Immunocore Holdings PLC - ADR

Inovio Pharmaceuticals Inc

Iovance Biotherapeutics Inc

Merck & Co Inc

Moderna Inc

Novo Nordisk A/S

Pfizer Inc

Vertex Pharmaceuticals, Inc.

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits Polls

Investors are weighing the company's first profitable quarter alongside $431 million in Q3 Rezdiffra sales against market volatility.

Traders are intensely debating whether the recent price action reflects genuine skepticism or orchestrated market manipulation.

The stock's strong sales growth and blockbuster status have sparked recurring speculation about a potential buyout by big pharma.

Discussions are heating up regarding the upcoming 2027 MAESTRO outcomes readouts and the expansion into the multi-billion dollar F4C market.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MDGL News